Virtual Library

Start Your Search

D. Wankhede



Author of

  • +

    Poster Display session (Friday) (ID 65)

    • Event: ELCC 2018
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
    • +

      107P - Meta-analysis on defining optimal follow up of patients with early stage NSCLC after definitive therapy (ID 260)

      12:30 - 13:00  |  Presenting Author(s): D. Wankhede

      • Abstract

      Background:
      This is a meta-analysis to evaluate the impact of various follow-up intensities and strategies on the outcome of patients after definitive therapy for early stage NSCLC.

      Methods:
      All the original RCTs comparing the follow-up protocols of different definitive therapies on early stage NSCLC were considered up to November 2017. Specifically, the Jadad score was used to evaluated and appraise the quality of the selected randomized trials.

      Results:
      In the five RCTs, a total of 1,826 patients with early stage NSCLC undergoing various definitive therapies were randomized into less intensive or minimal follow-up group (n = 984) and intensive follow-up (n = 842). The female: male ratio was 1: 1.45 and 1.26:1 in the intensive and less intensive follow-up groups, respectively. A critical evaluation of all the articles that were included in the present meta-analysis revealed that most of the patients that took part in the study had a follow-up of at least 3 years. Nonetheless, three studies reported a drop out rate that varied between zero and 7% for the less intensive follow-up category and from zero to 38.2% for the minimal or less intensive follow-up group.

      Conclusions:
      The meta-analysis revealed that in selected patients with stage IIIA-N2 NSCLC, surgical resection does not improve the overall survival rate as is the case with radiotherapy. None of the follow up protocols was associated with increase in recurrence rate or overall survival rate. The ideal follow up should be individualized.

      Clinical trial identification:


      Legal entity responsible for the study:
      Durgesh Wankhede

      Funding:
      Has not received any funding

      Disclosure:
      All authors have declared no conflicts of interest.